- Home
- VANI vs BBIO Comparison
VANI vs BBIO Comparison
Compare VANI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VANI | BBIO |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | 36 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.8M | 15.3B |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VANI | BBIO |
|---|---|---|
| Price | $1.20 | $75.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 22 |
| Target Price | $4.00 | ★ $79.45 |
| AVG Volume (30 Days) | 549.9K | ★ 3.2M |
| Earning Date | 03-30-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $353,780,000.00 |
| Revenue This Year | N/A | $129.08 |
| Revenue Next Year | N/A | $79.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.46 |
| 52 Week Low | $0.91 | $28.33 |
| 52 Week High | $1.92 | $84.94 |
Technical Indicators
Market Signals| Indicator | VANI | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 48.23 |
| Support Level | $1.16 | $70.09 |
| Resistance Level | $1.31 | $84.94 |
| Average True Range (ATR) | 0.09 | 4.29 |
| MACD | -0.03 | -0.29 |
| Stochastic Oscillator | 5.19 | 49.32 |
Price Performance
Historical ComparisonAbout VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.